Myasthenia Gravis.
Nils E Gilhus
https://pubmed.ncbi.nlm.nih.gov/28029925Actively Recruiting
Age: 16Years +
All Genders
ID05214612
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Led by Assiut University · Updated on 2024-07-31
30
Participants Needed
1
Research Sites
12 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying myasthenia gravis (MG), a rare autoimmune disease that causes muscle weakness. This study aims to describe different MG subgroups, understand how often they occur, and identify factors that predict how patients respond to treatment. It also seeks to find how common treatment-resistant MG is and to better understand disease relapse and management strategies. The study observes patients with MG who receive drug treatments, including therapies for disease crises like plasmapheresis. It tracks clinical features and treatment responses over time without assigning participants to different treatment groups. The study focuses on changes in muscle strength and quality of life, measured at enrollment and after three months. Participants will undergo assessments including muscle testing, quality of life questionnaires, and monitoring for treatment side effects. Researchers will collect samples and perform imaging and other evaluations related to the disease. The main outcomes are changes in MG-specific scales over three months and the frequency of treatment-related adverse effects. The study started in 2022 and is expected to end in March 2025.
CONDITIONS
Brief Title
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Who Can Participate
Age: 16Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Age 16 years and older
- Includes both males and females
- Clinical diagnosis of myasthenia gravis confirmed by response to pyridostigmine or nerve stimulation test showing >10% decrement
- Willingness to undergo sample collection, imaging studies, and other disease-related assessments
You will not qualify if you...
- Age younger than 16 years
- History of chronic psychiatric or neurological disorders other than myasthenia gravis causing weakness or fatigue
- Severe systemic illness affecting life expectancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - 3 months
Participants who receive standard drug treatment for myasthenia gravis and treatment of crisis such as plasmapheresis are observed to assess disease characteristics, treatment outcomes, and quality of life.
Baseline assessment and 3-month follow-up assessment
Trial Site Locations
Total: 1 location
1
Assiut University
Asyut, Egypt, 71515
Actively Recruiting
Loading map...
Research Team
N
Nourelhoda AA Haridy, Lecturer
E
Eman MH Khedr, Professor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
International consensus guidance for management of myasthenia gravis: Executive summary.
Donald B Sanders, Gil I Wolfe, Michael Benatar...
https://pubmed.ncbi.nlm.nih.gov/27358333Myasthenia gravis: new developments in research and treatment.
Amelia Evoli
https://pubmed.ncbi.nlm.nih.gov/28654435Myasthenia gravis.
Nils Erik Gilhus, Socrates Tzartos, Amelia Evoli...
https://pubmed.ncbi.nlm.nih.gov/31048702Update in immunosuppressive therapy of myasthenia gravis.
Agustina M Lascano, Patrice H Lalive
https://pubmed.ncbi.nlm.nih.gov/33197578Clinical characteristics of refractory myasthenia gravis patients.
Joome Suh, Jonathan M Goldstein, Richard J Nowak
https://pubmed.ncbi.nlm.nih.gov/23766745Treatment-refractory myasthenia gravis.
Nicholas J Silvestri, Gil I Wolfe
https://pubmed.ncbi.nlm.nih.gov/24872217Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry - The EXPLORE-MG registry.
Rahul Anil, Aditya Kumar, Sneha Alaparthi...
https://pubmed.ncbi.nlm.nih.gov/32388060Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.
A Jaretzki, R J Barohn, R M Ernstoff...
https://pubmed.ncbi.nlm.nih.gov/10921745